PROCEDURE
Forearm vascular study
Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
The Effect of Ischaemic-Reperfusion and Remote Ischaemic Preconditioning in Man - A Bradykinin Dependent Pathway
Status
Completed
Phase
Not applicable
Enrollment
12
Locations
1
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
Heart attacks are usually caused by a blood clot blocking an artery supplying blood to the heart. Current treatments are designed at relieving this blockage as quickly as possible to minimize damage to the heart muscle. However in restoring the supply of blood local damage known as "ischaemia-reperfusion injury" may occur. The aim of this study is to assess how clot forming and clot dissolving pathways are affected during this process, and examine the role of a natural inflammatory hormone, bradykinin. This will help the investigators to understand the mechanism by which ischaemia-reperfusion injury may occur and to devise new treatments for heart attacks.
Interventions
Treatment arms and agents.
DRUG
Placebo
Systemic infusion of placebo (saline)
DRUG
bradykinin receptor antagonist (HOE-140)
Systemic infusion of bradykinin receptor antagonist (HOE-140)
Timeline
From registration to results.
First posted
Aug 25, 2009
Study start
Aug 2009
Primary completion
Oct 2010
Study completion
Oct 2010
Results posted
Not reported
Registry updated
Oct 25, 2010
Outcomes
What the study measures.
Primary outcomes
Change in forearm blood flow in response to vasodilators (ACh(, ischaemia reperfusion and ischaemic preconditioning
Time frame · 20 fixed timepoints during each study visit (3hrs)
Secondary outcomes
Change in platelet-monocyte-binding after ischaemia reperfusion and ischaemic preconditioning
Time frame · 4 fixed timepoints during each study visit (3hrs)
Eligibility
Who can take part.
- Minimum age
- 18 Years
- Maximum age
- 65 Years
- Sex
- MALE
- Healthy volunteers
- Yes
Inclusion Criteria: * Healthy males between 18-65 years of ages. * Non-smokers. Exclusion Criteria: * Any concurrent illness or chronic medical condition. * Concurrent use of vasoactive medication. * Smoking history.
Study locations
1 registered sites.
United Kingdom. Showing up to 24 locations stored in the fast local snapshot.
University of Edinburgh, 49 Little France Crescent
Edinburgh, United Kingdom
Publications
Results and literature.
Related trials
More studies on Icatibant.
NCT IDStudyPhase / statusEnrollmentUpdated
A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema
Takeda · Hereditary Angioedema (HAE)
Not applicable
Completed
32
2026-07
Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor
Vanderbilt University Medical Center · Intradialytic Hypotension
Phase 3
Recruiting
26
2026-04
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
QuantumLeap Healthcare Collaborative · COVID-19
Phase 2
Active, not recruiting
1,500
2026-03
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
Takeda · Hereditary Angioedema (HAE)
Not applicable
Completed
115
2026-01
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
KalVista Pharmaceuticals, Ltd. · Hereditary Angioedema
Not applicable
Completed
88
2026-01
A Study to Evaluate the Safety and Efficacy of Icatibant in Patients With Bradykinin Induced Angioedema
Nang Kuang Pharmaceutical Co., Ltd. · Bradykinin-mediated Angioedema · Hereditary Angioedema (HAE)
Phase 4
Completed
5
2025-12
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2
Vanderbilt University Medical Center · Heart Failure
Phase 4
Completed
46
2025-08
FIRAZYR General Drug Use-Results Survey (Japan)
Shire · Hereditary Angioedema (HAE)
Not applicable
Completed
179
2025-02
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.